Endpoints News | DEc 20, 2023

Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates

Fierce Biotech | Dec 20, 2023

Sanofi-backed Sudo scores $116M for TYK2 MS, psoriasis candidates

Pharma Letter | Dec 20, 2023

Sudo Biosciences raises $116 million in Series B financing

Medcity News | Oct 2, 2022

BMS was first but startup Sudo Bio aims to be best at blocking key autoimmune target

Endpoints News | Sep 28, 2022

Bristol Myers got the first TYK2 approval. Frazier’s new biotech Sudo hopes to get many more